Showing 5711-5720 of 7297 results for "".
- Consensus: Straight-Line Vector Planning Produces Best Silhouette InstaLift Resultshttps://practicaldermatology.com/news/consensus-straight-line-vector-planning-produces-best-silhouette-instalift-results/2457668/Straight-line vector planning produces the ideal lifting effect and sets the stage for maximum collagen regeneration with the Silhouette InstaLift, according to a study in the July 2018 issue of Journal of Drugs in Dermat
- Catch a Sneak Peek of Ground Up Season 2 at Summer AADhttps://practicaldermatology.com/news/get-a-sneak-peek-of-ground-up-season-2-at-summer-aad/2457671/The publishers of Practical Dermatology® and Modern Aesthetics® magazines are offering a sneak peek of the coming new season of the acclaimed video series, Ground Up, at Summer AAD in Chicago. Ground Up Season 1 took viewers
- SENTÉ Launches Dermal Contour Pressed Serumhttps://practicaldermatology.com/news/sent-launches-dermal-contour-pressed-serum/2457670/Senté's Dermal Contour Pressed Serum with 3 glycosaminoglycan analogs to help tighten skin for a more youthful contour is now availalbe. Patented Heparan Sulfate Analog (HSA) combined with Dermatan Sulfate Analog (DSA) and Chondroitin, Sulfate Analog (CSA), the company's proprietar
- Link Between Diet and Skin Disease Takes Center Stage at Summer AADhttps://practicaldermatology.com/news/link-between-diet-and-skin-disease-takes-center-stage-at-summer-aad/2457672/Dermatologists must help patients determine if there are any foods that may cause their skin condition to flare and provide evidence-based recommendations about next steps. “People looking to improve their skin health may think that changing their diet is the answer, but a derm
- Skin Cancer Risk Varies Based on Organ Transplant Patients' Skin Tonehttps://practicaldermatology.com/news/skin-cancer-risk-varies-based-on-organ-transplant-patients-skin-tone/2457673/Dermatologists must know how to evaluate organ transplant patients’ unique risk factors for skin cancer and counsel these patients accordingly. “Individuals who receive organ transplants need to take immunosuppressive medications for the rest of their lives, and this makes it
- AAD: Research Shows Free Skin Cancer Screenings Can Help Save Liveshttps://practicaldermatology.com/news/aad-research-shows-free-skin-cancer-screenings-can-help-save-lives/2457675/Data indicates that American Academy of Dermatology’s (AAD's) SPOTme program serves an important need. While skin cancer can be deadly, it is also highly treatable when detected early. In fact, melanoma, the deadliest form of skin cancer, has a five-year survival rate of 95 percen
- iRestore Expands Reseller Programhttps://practicaldermatology.com/news/irestore-expands-reseller-program/2457677/The iRestore Laser Hair Growth System from Freedom Laser Therapy is now more widely available, thanks to an expanded reseller program for the drug-free, pain-free laser hair restoration device. The reseller program now offers an affiliate model that enables sales representative
- Núria Perez-Cullell Appointed CEO of Pierre Fabre Dermo-Cosmeticshttps://practicaldermatology.com/news/nria-perez-cullell-appointed-ceo-of-pierre-fabre-dermo-cosmetics/2457679/Ms. Núria PerezCullell is the new CEO of The Pierre Fabre Group’s Pierre Fabre Dermo-Cosmetics (PFDC) subsidiary. This appointment will take effect on August 20, 2018. Núria Perez-Cullell will take over from Mr. Eric Ducournau, whose appointment to the position of Pier
- Pulse Biosciences: First Patients Treated in Study of Sebaceous Hyperplasia Lesionshttps://practicaldermatology.com/news/pulse-biosciences-first-patients-treated-in-study-of-sebaceous-hyperplasia-lesions/2457682/Pulse Biosciences, Inc. says the first patients have been treated in its multi-center study to evaluate the safety and efficacy of its Nano-Pulse Stimulation (NPS) technology for eliminating Sebaceous Hyperplasia (SH). SH is an unsightly benign skin lesion that typically appears on facial skin an
- BioPharmX: FDA Grants CARC Waiver; Post-Hoc Analysis for BPX-01 Completehttps://practicaldermatology.com/news/biopharmx-fda-grants-carc-waiver-post-hoc-analysis-for-bpx-01-complete/2457686/The FDA has waived its requirement for a dermal carcinogenicity study for BPX-01 from BioPharmX Corporation, eliminating several years of non-clinical research normally required for FDA review. BPX-01, a novel topical gel formulation of minocycline for the treatment of inflammatory